QQQ   352.33 (+1.01%)
AAPL   179.93 (+1.19%)
MSFT   324.82 (+0.45%)
META   265.48 (+0.71%)
GOOGL   122.11 (-0.32%)
AMZN   123.78 (+2.10%)
TSLA   232.74 (+3.64%)
NVDA   385.42 (+2.85%)
NIO   7.68 (-1.03%)
BABA   86.37 (+1.28%)
AMD   120.92 (+2.62%)
T   16.00 (-0.62%)
F   13.56 (-0.22%)
MU   65.08 (-2.95%)
CGC   0.70 (-2.73%)
GE   106.85 (+0.73%)
DIS   92.35 (-0.18%)
AMC   4.67 (-1.27%)
PFE   39.04 (+0.39%)
PYPL   64.18 (+0.22%)
NFLX   404.96 (+1.30%)
QQQ   352.33 (+1.01%)
AAPL   179.93 (+1.19%)
MSFT   324.82 (+0.45%)
META   265.48 (+0.71%)
GOOGL   122.11 (-0.32%)
AMZN   123.78 (+2.10%)
TSLA   232.74 (+3.64%)
NVDA   385.42 (+2.85%)
NIO   7.68 (-1.03%)
BABA   86.37 (+1.28%)
AMD   120.92 (+2.62%)
T   16.00 (-0.62%)
F   13.56 (-0.22%)
MU   65.08 (-2.95%)
CGC   0.70 (-2.73%)
GE   106.85 (+0.73%)
DIS   92.35 (-0.18%)
AMC   4.67 (-1.27%)
PFE   39.04 (+0.39%)
PYPL   64.18 (+0.22%)
NFLX   404.96 (+1.30%)
QQQ   352.33 (+1.01%)
AAPL   179.93 (+1.19%)
MSFT   324.82 (+0.45%)
META   265.48 (+0.71%)
GOOGL   122.11 (-0.32%)
AMZN   123.78 (+2.10%)
TSLA   232.74 (+3.64%)
NVDA   385.42 (+2.85%)
NIO   7.68 (-1.03%)
BABA   86.37 (+1.28%)
AMD   120.92 (+2.62%)
T   16.00 (-0.62%)
F   13.56 (-0.22%)
MU   65.08 (-2.95%)
CGC   0.70 (-2.73%)
GE   106.85 (+0.73%)
DIS   92.35 (-0.18%)
AMC   4.67 (-1.27%)
PFE   39.04 (+0.39%)
PYPL   64.18 (+0.22%)
NFLX   404.96 (+1.30%)
QQQ   352.33 (+1.01%)
AAPL   179.93 (+1.19%)
MSFT   324.82 (+0.45%)
META   265.48 (+0.71%)
GOOGL   122.11 (-0.32%)
AMZN   123.78 (+2.10%)
TSLA   232.74 (+3.64%)
NVDA   385.42 (+2.85%)
NIO   7.68 (-1.03%)
BABA   86.37 (+1.28%)
AMD   120.92 (+2.62%)
T   16.00 (-0.62%)
F   13.56 (-0.22%)
MU   65.08 (-2.95%)
CGC   0.70 (-2.73%)
GE   106.85 (+0.73%)
DIS   92.35 (-0.18%)
AMC   4.67 (-1.27%)
PFE   39.04 (+0.39%)
PYPL   64.18 (+0.22%)
NFLX   404.96 (+1.30%)
NASDAQ:TMCI

Treace Medical Concepts (TMCI) Stock Forecast, Price & News

$26.25
+0.01 (+0.04%)
(As of 02:27 PM ET)
Compare
Today's Range
$25.57
$26.25
50-Day Range
$24.49
$27.81
52-Week Range
$13.19
$27.97
Volume
108,582 shs
Average Volume
381,996 shs
Market Capitalization
$1.61 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$29.60

Treace Medical Concepts MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.80 Rating Score
Upside/​Downside
13.6% Upside
$29.60 Price Target
Short Interest
Healthy
3.28% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.52mentions of Treace Medical Concepts in the last 14 days
Based on 10 Articles This Week
Insider Trading
Selling Shares
$8.04 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($0.71) to ($0.58) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.92 out of 5 stars

Medical Sector

600th out of 981 stocks

Surgical & Medical Instruments Industry

57th out of 99 stocks


TMCI stock logo

About Treace Medical Concepts (NASDAQ:TMCI) Stock

Treace Medical Concepts, Inc., an orthopedic medical device company, engages in the design, manufacture, and marketing of medical devices for foot and ankle surgeons in the United States. It offers Lapiplasty procedure that allows podiatric surgeons to treat all three dimensions of the bunion, providing patients with a cosmetic and medical improvement. The company also provides Lapiplasty Mini-Incision precision system. In addition, it offers products to address ancillary surgical procedures, including akin osteotomies, weil osteotomies, intercuneiform stabilization, lesser tarsometatarsal joint fusions, and autograft bone harvesting, as well as for MTP fusion. Treace Medical Concepts, Inc. was founded in 2013 and is headquartered in Ponte Vedra Beach, Florida.

Receive TMCI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Treace Medical Concepts and its competitors with MarketBeat's FREE daily newsletter.

TMCI Stock News Headlines

New "Mined in America" Lithium Opportunities?
The average electric vehicle needs 138 pounds of lithium carbonate for its battery components. But China currently controls the entire lithium supply chain.
BTIG Sticks to Its Buy Rating for Treace Medical Concepts (TMCI)
What 5 Analyst Ratings Have To Say About Treace Medical Concepts
New "Mined in America" Lithium Opportunities?
The average electric vehicle needs 138 pounds of lithium carbonate for its battery components. But China currently controls the entire lithium supply chain.
Treace Medical Concepts (TMCI) Gets a Buy from BTIG
Q1 2023 Treace Medical Concepts Inc Earnings Call
See More Headlines

TMCI Price History

TMCI Company Calendar

Last Earnings
5/08/2023
Today
6/08/2023
Next Earnings (Estimated)
8/08/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Surgical & medical instruments
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:TMCI
Fax
N/A
Employees
248
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$29.60
High Stock Price Forecast
$33.00
Low Stock Price Forecast
$26.00
Forecasted Upside/Downside
+12.8%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.80
Research Coverage
5 Analysts

Profitability

Net Income
$-42,810,000.00
Pretax Margin
-30.48%

Debt

Sales & Book Value

Annual Sales
$141.84 million
Book Value
$1.09 per share

Miscellaneous

Free Float
43,735,000
Market Cap
$1.61 billion
Optionable
Not Optionable
Beta
-0.01

Key Executives

  • Mr. John T. TreaceMr. John T. Treace (Age 51)
    CEO, Founder & Director
    Comp: $688.14k
  • Mr. Mark L. Hair CPA (Age 52)
    Chief Financial Officer
    Comp: $688.22k
  • Mr. Aaron Berutti (Age 44)
    Sr. VP of Sales
    Comp: $323.62k
  • Mr. Terry W. Lubben (Age 58)
    Sr. VP of Operations
  • Mr. Scot Elder (Age 48)
    Chief Legal & Compliance Officer and Corp. Sec.
  • Dr. Sean F. Scanlan Ph.D. (Age 41)
    Sr. VP of Marketing
  • Mr. Daniel E. Owens (Age 51)
    Chief HR Officer
  • Mr. Jaime A. Frias (Age 61)
    Chief Bus. Devel. Officer
  • Ms. Shana Zink
    Sr. VP of Clinical Affairs, Medical Education & Reimbursement
  • Ms. Rachel Osbeck
    Sr. VP of Quality Assurance & Regulatory Affairs













TMCI Stock - Frequently Asked Questions

Should I buy or sell Treace Medical Concepts stock right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Treace Medical Concepts in the last twelve months. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" TMCI shares.
View TMCI analyst ratings
or view top-rated stocks.

What is Treace Medical Concepts' stock price forecast for 2023?

5 analysts have issued 1 year price targets for Treace Medical Concepts' shares. Their TMCI share price forecasts range from $26.00 to $33.00. On average, they predict the company's share price to reach $29.60 in the next year. This suggests a possible upside of 12.8% from the stock's current price.
View analysts price targets for TMCI
or view top-rated stocks among Wall Street analysts.

How have TMCI shares performed in 2023?

Treace Medical Concepts' stock was trading at $22.99 on January 1st, 2023. Since then, TMCI shares have increased by 14.1% and is now trading at $26.24.
View the best growth stocks for 2023 here
.

When is Treace Medical Concepts' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 8th 2023.
View our TMCI earnings forecast
.

How were Treace Medical Concepts' earnings last quarter?

Treace Medical Concepts, Inc. (NASDAQ:TMCI) announced its earnings results on Monday, May, 8th. The company reported ($0.23) EPS for the quarter, meeting analysts' consensus estimates of ($0.23). The firm earned $42.20 million during the quarter, compared to analyst estimates of $39.48 million. Treace Medical Concepts had a negative trailing twelve-month return on equity of 48.57% and a negative net margin of 30.48%.

What ETFs hold Treace Medical Concepts' stock?

ETFs with the largest weight of Treace Medical Concepts (NASDAQ:TMCI) stock in their portfolio include SPDR S&P Health Care Equipment ETF (XHE), Principal Healthcare Innovators ETF (BTEC), iShares U.S. Medical Devices ETF (IHI),

What guidance has Treace Medical Concepts issued on next quarter's earnings?

Treace Medical Concepts updated its FY 2023 earnings guidance on Monday, May, 8th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $190.00 million-$196.00 million, compared to the consensus revenue estimate of $190.54 million.

When did Treace Medical Concepts IPO?

(TMCI) raised $150 million in an initial public offering (IPO) on Friday, April 23rd 2021. The company issued 9,400,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan and Morgan Stanley acted as the underwriters for the IPO and SVB Leerink and Stifel were co-managers.

What is Treace Medical Concepts' stock symbol?

Treace Medical Concepts trades on the NASDAQ under the ticker symbol "TMCI."

Who are Treace Medical Concepts' major shareholders?

Treace Medical Concepts' stock is owned by many different institutional and retail investors. Top institutional shareholders include BlackRock Inc. (4.24%), Perceptive Advisors LLC (3.99%), Next Century Growth Investors LLC (2.51%), CIBC Private Wealth Group LLC (2.30%), Emerald Advisers LLC (2.23%) and Emerald Mutual Fund Advisers Trust (1.83%). Insiders that own company stock include Aaron Berutti, Daniel E Owens, F Barry Bays, Jaime A Frias, James T Treace, John R Treace, John T Treace, Mark Hair, Richard W Mott, Scot Michael Elder, Sean F Scanlan, Terry W Lubben and Thomas E Timbie.
View institutional ownership trends
.

How do I buy shares of Treace Medical Concepts?

Shares of TMCI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Treace Medical Concepts' stock price today?

One share of TMCI stock can currently be purchased for approximately $26.24.

How much money does Treace Medical Concepts make?

Treace Medical Concepts (NASDAQ:TMCI) has a market capitalization of $1.61 billion and generates $141.84 million in revenue each year. The company earns $-42,810,000.00 in net income (profit) each year or ($0.84) on an earnings per share basis.

How many employees does Treace Medical Concepts have?

The company employs 248 workers across the globe.

How can I contact Treace Medical Concepts?

Treace Medical Concepts' mailing address is 203 FORT WADE RD. SUITE 150, PONTE VEDRA FL, 32081. The official website for the company is www.treace.com. The company can be reached via phone at 904-373-5940 or via email at ir@treace.net.

This page (NASDAQ:TMCI) was last updated on 6/8/2023 by MarketBeat.com Staff

My Account -